Is the show over for CYC in ANCA-associated vasculitis? Rheumatology Update WASHINGTON: Cyclophosphamide continues to have a role in ANCA-associated vasculitis but rituximab can be considered a valid option for newly diagnosed patients with severe disease, the conference has heard. In a session coined the 'great debate' Dr ... |
